

USSN 10/769,725

PH-7148A-DIV1

Remarks

Status of the claims. Claims 1-15 are cancelled. Claims 16-20 are pending. Claims 18 and 20 are withdrawn from consideration.

Claim 16 has been rewritten to generically encompass claim 17. The applicants thank the examiner for pointing out the improper dependency. Support for A being A²-A³-A⁴-A⁵-A⁶ and for A²-A³-A⁴-A⁵-A⁶ being Asp-Glu-Val-Val-Pro is on page 69, line 21 - page 70, line 8. Support for R³ being H is on page 43, line 20.

Election of invention. The applicants elect group II with traverse. The applicants believe the core structure of claims 16, 17, and 18 is novel and that a search of this moiety is necessarily a search of both group I, II, and III. Therefore it is not an undue burden to examine all of these inventions. The applicants also note and reserve their right to rejoin process of use claims (claim 20) for allowed compound claims under MPEP 821.04.

Claims 16, 17, and 19 read on the elected invention.


Election of species. The applicants elect the compound of Example 3 (H-Asp-Glu-Val-Val-Pro-(1R)-1-amino-3-phenylpropylboronic acid (+)-pinanediol ester; page 93). Claims 16, 17, and 19 read on the elected species.

If any issues remain, the examiner is respectfully invited to contact the applicants' agent, James Epperson, by phone (203-677-6974), fax (203-677-6900), or e-mail (james.epperson@bms.com).

Respectfully yours,

Date: 11/11/2004

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000



James Epperson
Agent for Applicants
Reg. No. 52,867
Phone: (203) 677-6974